Conversations on Commercialization: Changing the Name Game with Addison Whitney’s Ari™

A new limited series of the Syneos Health Podcast, Conversations on Commercialization unpacks how biopharma leaders are rewriting the commercial playbook, redefining what it takes to succeed. What if drug naming could be faster, smarter and more aligned to brand strategy? In this episode, Addison Whitney’s Joe Daley, President, and Bill Purdy, SVP and Managing Director of Global Brand Development & Strategy, break down how Ari™, a purpose-built AI platform, is solving long-standing naming and branding challenges in biopharma. Listen and you’ll learn: How Ari™ integrates strategic input, trademark search and POCA screening Ways AI reduces attrition and regulatory risk in naming Why naming is now a strategic process and not just a creative one The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].